OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic.
null nullHelen J CurtisBrian MackennaAlex J WalkerRichard CrokerAmir MehrkarCaroline E MortonSebastian C J BaconGeorge HickmanPeter InglesbyChristopher BatesDavid EvansTom WardJonathan CockburnSimon DavyKrishnan BhaskaranAnna SchultzeChristopher T RentschElizabeth WilliamsonWilliam J HulmeLaurie A TomlinsonRohini MathurHenry DrysdaleRosalind M M EggoAngel Yun WongHarriet J ForbesJohn ParryFrank HesterSam HarperIan J DouglasLiam SmeethAlex J WalkerPublished in: Open heart (2021)
Increased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people coprescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic.